Shares of Alembic Pharmaceuticals Ltd surged more than 2% on 28 July after the company announced securing final approval from the USFDA for Carbamazepine Extended-Release tablets USP, 100 mg, 200 mg, and 400 mg.

In its stock market filing, the company declared that “Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Carbamazepine extended-release tablets USP, 100 mg, 200 mg, and 400 mg.”

The authorised ANDA is therapeutically similar to Novartis Pharmaceuticals Corporation’s Tegretol-XR extended-release tablets in strengths of 100 mg, 200 mg, and 400 mg.

Carbamazepine tablets are used as both an anticonvulsant and to relieve the pain associated with genuine trigeminal neuralgia.

Alembic has received 225 ANDA approvals from the USFDA, including 202 final and 23 tentative clearances.

Furthermore, the company’s board of directors will meet on 5 August 2025 to evaluate and approve unaudited financial results for the quarter ended 30 June 2025.

Moreover, Dr. Sachin Ghosalkar has been appointed as Sr. Vice President – SCM & Operations, with effect from 21 July 2025.

At 12:35 pm, the shares of Alembic Pharma were trading 0.35% higher at Rs 1,001 on NSE. 

Tired of missing hot stocks? Unicorn Signals provides powerful tools like stock scans and more help you make informed trading decisions. Download now and take control of your portfolio!